1. Home
  2. UAMY vs DMRA Comparison

UAMY vs DMRA Comparison

Compare UAMY & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo United States Antimony Corporation

UAMY

United States Antimony Corporation

HOLD

Current Price

$10.77

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

DMRA

Damora Therapeutics Inc. Common Stock

N/A

Current Price

$26.23

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UAMY
DMRA
Founded
1968
2011
Country
United States
United States
Employees
N/A
7
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.6B
IPO Year
1997
2020

Fundamental Metrics

Financial Performance
Metric
UAMY
DMRA
Price
$10.77
$26.23
Analyst Decision
Strong Buy
Buy
Analyst Count
5
1
Target Price
$9.44
$46.00
AVG Volume (30 Days)
9.9M
242.1K
Earning Date
05-07-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$39,257,708.00
N/A
Revenue This Year
$219.89
N/A
Revenue Next Year
$104.28
N/A
P/E Ratio
N/A
N/A
Revenue Growth
162.80
N/A
52 Week Low
$1.94
$16.50
52 Week High
$19.71
$28.57

Technical Indicators

Market Signals
Indicator
UAMY
DMRA
Relative Strength Index (RSI) 60.29 53.98
Support Level $10.68 $23.65
Resistance Level $11.01 $27.75
Average True Range (ATR) 0.86 2.19
MACD 0.24 0.17
Stochastic Oscillator 79.36 63.08

Price Performance

Historical Comparison
UAMY
DMRA

About UAMY United States Antimony Corporation

United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has two operating segments: antimony and zeolite. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the United States, Canada, and Mexico, of which the vast majority of its revenue comes from the United States.

About DMRA Damora Therapeutics Inc. Common Stock

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Share on Social Networks: